


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:53Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407139" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407139</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>kidney360</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney360</journal-id><journal-id journal-id-type="iso-abbrev">Kidney360</journal-id><journal-id journal-id-type="pmc-domain-id">4060</journal-id><journal-id journal-id-type="pmc-domain">kidney360</journal-id><journal-id journal-id-type="publisher-id">Kidney360</journal-id><journal-title-group><journal-title>Kidney360</journal-title></journal-title-group><issn pub-type="epub">2641-7650</issn><publisher><publisher-name>American Society of Nephrology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407139</article-id><article-id pub-id-type="pmcid-ver">PMC12407139.1</article-id><article-id pub-id-type="pmcaid">12407139</article-id><article-id pub-id-type="pmcaiid">12407139</article-id><article-id pub-id-type="pmid">40875528</article-id><article-id pub-id-type="doi">10.34067/KID.0000000938</article-id><article-id pub-id-type="publisher-id">K360-2025-000727</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Desmopressin Use before Kidney Biopsy</article-title><subtitle>The Controversy Continues</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5988-4400</contrib-id><name name-style="western"><surname>Almehmi</surname><given-names initials="A">Ammar</given-names></name><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="http://credit.niso.org/contributor-roles/data-curation/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><aff>Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama</aff></contrib-group><author-notes><corresp><bold>Correspondence:</bold> Dr. Ammar Almehmi, email: <email>aalmehmi@uabmc.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>8</month><year>2025</year></pub-date><volume>6</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">496170</issue-id><fpage>1259</fpage><lpage>1261</lpage><pub-history><event event-type="pmc-release"><date><day>28</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="kidney360-6-1259.pdf"/><self-uri xlink:href="kidney360-6-1259.pdf"/><related-article related-article-type="companion" xml:lang="en" xlink:title="research-article" journal-id="Kidney360" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12407119"><article-title>Effect of Desmopressin on Post Kidney Biopsy Bleeding Complications in Patients with Reduced Kidney Function</article-title><volume>6</volume><issue>8</issue><date><day>11</day><month>3</month><year>2025</year></date><fpage>1350</fpage><lpage>1356</lpage><source>Kidney360</source><pub-id pub-id-type="doi">10.34067/KID.0000000760</pub-id><pub-id pub-id-type="pmcid">PMC12407119</pub-id><pub-id pub-id-type="pmid">40067357</pub-id></related-article><kwd-group><kwd>access blood flow</kwd><kwd>AKI</kwd><kwd>arteriovenous access</kwd><kwd>arteriovenous fistula</kwd><kwd>hemodialysis</kwd><kwd>hemodialysis</kwd><kwd>hypertension</kwd><kwd>kidney</kwd><kwd>peritoneal dialysis</kwd><kwd>uremia</kwd></kwd-group><counts><fig-count count="0"/><table-count count="1"/><ref-count count="10"/><page-count count="3"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>Read-along</meta-name><meta-value>YES</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Percutaneous kidney biopsy (PKB) is an invasive procedure that provides valuable information about diagnosis, treatment, and prognosis of kidney pathologies.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p><p>Currently, most PKB procedures are performed under real-time ultrasound (US) guidance and use an automated spring-loaded gun. Despite these advancements, this invasive procedure carries a considerable risk of bleeding complications that are mainly related to the injury of the blood vessels, perinephric area, and collecting system.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p><p>Bleeding complications are generally classified into minor (such as gross hematuria, perinephric hematoma) and major (hematoma that requires blood transfusion, blood transfusion, and bleeding that requires invasive intervention to control).<sup><xref rid="B1" ref-type="bibr">1</xref></sup> In a large meta-analysis, Poggio <italic toggle="yes">et al.</italic> reviewed 118,064 PKBs and found that the occurrence of gross hematuria and bleeding requiring transfusion were 3.5% and 1.6%, respectively.<sup><xref rid="B2" ref-type="bibr">2</xref></sup></p><p>Another series of more than 1000 PKBs found that the rate of the overall, minor, and major bleeding complications was 14.7%, 8.1%, and 6.6%, respectively.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> The major complications are associated with significant morbidity and often lead to prolonged hospital stay.</p><p>Fortunately, most of these complications are silent clinically and resolve spontaneously using simple measures such as placing the patient in a supine position for few hours after the procedure.</p><p>Real-time US is the most common modality used to detect these complications due to its wide availability and noninvasiveness. Accumulating evidence suggests that the absence of perinephric hematoma within the first hour after PKB is highly predictive of a noncomplicated course.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p><p>Several risk factors are reported in the literature that increase the rate of these complications including older age, female sex, uncontrolled hypertension, steroid use, coagulopathy, reduced eGFR, and more than five needle passes during PKB procedure.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> In clinical practice, most of the efforts are centered around controlling the modifiable factors such as hypertension and coagulopathy to mitigate the bleeding risk.</p><p>It is well acknowledged that decreased eGFR and uremia are associated with platelet and endothelial dysfunction and defective interaction between the vessel wall and platelets. It is postulated that uremic milieu is associated with decreased vWf levels and impaired platelet aggregation.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> Since AKI and worsening kidney function are the most common indications for PKB, strategies that reduce the uremia-related bleeding complications are warranted.</p><p>Desmopressin acetate, known as 1-deamino 8-D-arginine vasopressin, is a selective agonist of type 2 vasopressin receptors that has been used as a hemostatic agent in minor surgeries and other invasive procedures for various congenital and acquired bleeding disorders.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> The hemostatic effect of 1-deamino 8-D-arginine vasopressin is attributed to the release of factor 8 and vWF from the endothelial cells and the improvement of platelet adhesion to the vessel wall.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref></sup></p><p>It is within this context that desmopressin acetate was proposed to address the bleeding predisposition in uremia and, hence, was used prophylactically before PKB to mitigate the bleeding complications. In fact, several observational and retrospective studies were conducted to examine the hemostatic role of desmopressin in controlling hemorrhagic complications of PKB.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> However, the outcomes of these studies were mixed producing conflicting evidence for clinical application. The conflicting data are likely related to several factors such as selection bias, single-center experience, the retrospective nature of these studies, the heterogeneity of inclusion criteria, and the variation in desmopressin dosing and route of administration.</p><p>To address these weaknesses and overcome the limitations of retrospective observational studies, randomized clinical trials (RCTs) were necessary to assess the efficacy of desmopressin in preventing the bleeding complications after PKB procedures. The first RCT was conducted by Manno <italic toggle="yes">et al.</italic> who enrolled 162 patients with a mean age of 40.6&#177;14.6 years from a single center in Italy with a serum creatinine of &#8804;1.5 mg/dl (eGFR &#8805;60 ml/min per 1.73 m<sup>2</sup>). The participants were randomized to either normal saline or a single dose of subcutaneous 0.3 <italic toggle="yes">&#956;</italic>g/kg of desmopressin given 1 hour before the procedure. Compared with the control group, there was reduced rate of hematomas on US performed immediately and 24 hours after PKB.<sup><xref rid="B6" ref-type="bibr">6</xref></sup></p><p>In a prospective multicenter cohort study between 2006 and 2015, Peters <italic toggle="yes">et al.</italic> analyzed 576 native PKBs in patients with serum creatinine &#8805;1.7 mg/dl from the Swedish registry, in which 204 patients received subcutaneous 0.3 <italic toggle="yes">&#956;</italic>g/kg before PKB. There was no difference in the minor and major bleeding complications between the two groups.<sup><xref rid="B7" ref-type="bibr">7</xref></sup></p><p>In the current issue, Chakrabarti <italic toggle="yes">et al.</italic> sought to examine the effect on desmopressin on bleeding complications after PKB in a double blinded randomized fashion.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> They randomized the participants into two groups: the intervention group (<italic toggle="yes">n</italic>=74; received 3 <italic toggle="yes">&#956;</italic>g/kg of desmopressin intranasally 1 hour before procedure) and the control group (<italic toggle="yes">n</italic>=78; received intranasal saline). The PKB procedure and clinical monitoring were standardized. Follow-up kidney US was performed at 6 and 24 hours after procedure. Although the incidence of minor or major bleeding complications was the primary outcome, the size of the perinephric hematomas seen on US at 6 and 24 hours after PKB was the secondary outcome. Expectedly, both post-PKB serum sodium and hemoglobin were lower in the intervention group. These findings are consistent with other studies and likely attributed to the desmopressin effect on distal tubule and collecting system leading to increased water reabsorption and plasma expansion. On average, hemoglobin concentration dropped by 0.67 g/dl in desmopressin group as compared with 0.26 g/dl in the control group (<italic toggle="yes">P</italic> = 0.002), a drop that is clinically insignificant.</p><p>Surprisingly, the rate of the overall complications in the current trial was high at 42% as compared with 14.7% observed in a large series of 1055 PKBs.<sup><xref rid="B3" ref-type="bibr">3</xref></sup></p><p>Moreover, the use of desmopressin in the current investigation did not reduce the rate of bleeding complications, a finding that is similar to another RCT, in which the use of desmopressin did not decrease the rate of major complications and paradoxically increased the rate of minor complications.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p><p>Overall, the findings of the current RCT are inconsistent with the outcomes of other RCTs, which are summarized in Table <xref rid="t1" ref-type="table">1</xref>. For instance, Peters <italic toggle="yes">et al.</italic> demonstrated that the group that received desmopressin had a lower overall complication rate (3.4% versus 8.4%, <italic toggle="yes">P</italic> = 0.03).<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Similarly, Prasad <italic toggle="yes">et al.</italic> showed that the use of desmopressin before PKB, as compared with placebo, reduced the incidence of bleeding (11.9% versus 33.3%, <italic toggle="yes">P</italic> = 0.0003) and the hematoma formation with a relative risk of 0.365 (95% confidence interval, 0.196 to 0.648; <italic toggle="yes">P</italic> = 0.0007).<sup><xref rid="B5" ref-type="bibr">5</xref></sup></p><table-wrap position="float" id="t1" orientation="portrait"><label>Table 1</label><caption><p>Summary of the available randomized clinical trials that used desmopressin before kidney biopsy</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Name of study/Year</th><th align="center" rowspan="1" colspan="1">Total No. Patients (No. Desmopressin)</th><th align="center" rowspan="1" colspan="1">Mean Age&#177;SD Year</th><th align="center" rowspan="1" colspan="1">Mean eGFR, ml/min per 1.73 m<sup>2</sup></th><th align="center" rowspan="1" colspan="1">Needle Size</th><th align="center" rowspan="1" colspan="1">Route of Desmopressin Administration</th><th align="center" rowspan="1" colspan="1">Postbiopsy US</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Manno <italic toggle="yes">et al.</italic><sup><xref rid="B6" ref-type="bibr">6</xref></sup> 2011<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">162 (82)</td><td align="center" rowspan="1" colspan="1">40.6&#177;14.6</td><td align="center" rowspan="1" colspan="1">&#8805;60</td><td align="center" rowspan="1" colspan="1">16G</td><td rowspan="1" colspan="1">0.3 <italic toggle="yes">&#956;</italic>g/kg subcutaneous</td><td rowspan="1" colspan="1">24 h after biopsy</td></tr><tr><td rowspan="1" colspan="1">Peters <italic toggle="yes">et al.</italic><sup><xref rid="B7" ref-type="bibr">7</xref></sup> 2018<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">576 (204)</td><td align="center" rowspan="1" colspan="1">58.5&#177;17.0</td><td align="center" rowspan="1" colspan="1">22.4</td><td align="center" rowspan="1" colspan="1">16G, 18G</td><td rowspan="1" colspan="1">0.3 <italic toggle="yes">&#956;</italic>g/kg subcutaneous</td><td rowspan="1" colspan="1">Not reported</td></tr><tr><td rowspan="1" colspan="1">Sethi <italic toggle="yes">et al.</italic><sup><xref rid="B9" ref-type="bibr">9</xref></sup> 2024<xref rid="tblfn3" ref-type="table-fn"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1">80 (40)</td><td align="center" rowspan="1" colspan="1">44.07&#177;12.7</td><td align="center" rowspan="1" colspan="1">20.82</td><td align="center" rowspan="1" colspan="1">16G</td><td rowspan="1" colspan="1">150 <italic toggle="yes">&#956;</italic>g intranasal</td><td rowspan="1" colspan="1">Immediately after biopsy</td></tr><tr><td rowspan="1" colspan="1">Prasad <italic toggle="yes">et al.</italic><sup><xref rid="B5" ref-type="bibr">5</xref></sup> 2025<xref rid="tblfn4" ref-type="table-fn"><sup>d</sup></xref></td><td align="center" rowspan="1" colspan="1">203(101)</td><td align="center" rowspan="1" colspan="1">40.60&#177;15.21</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">18G</td><td rowspan="1" colspan="1">300 <italic toggle="yes">&#956;</italic>g intranasal</td><td rowspan="1" colspan="1">0, 2, 6 h after biopsy</td></tr><tr><td rowspan="1" colspan="1">Chakrabati <italic toggle="yes">et al.</italic><sup><xref rid="B8" ref-type="bibr">8</xref></sup> 2025<xref rid="tblfn5" ref-type="table-fn"><sup>e</sup></xref></td><td align="center" rowspan="1" colspan="1">152 (74)</td><td align="center" rowspan="1" colspan="1">39.15&#177;15</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">16G</td><td rowspan="1" colspan="1">3 <italic toggle="yes">&#956;</italic>g/kg intranasal</td><td rowspan="1" colspan="1">6, 24 h after biopsy</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>US, ultrasound.</p></fn><fn id="tblfn1"><label>a</label><p>Bleeding complications were classified as major (fistula formation, requirement for transfusion), minor (hematuria and hematoma 2x2 cm); hematoma size was a secondary outcome.</p></fn><fn id="tblfn2"><label>b</label><p>Bleeding complications were classified as major (hydronephrosis, requirement for transfusion, septicemia); minor (hematuria).</p></fn><fn id="tblfn3"><label>c</label><p>Bleeding complications were classified as major (requirement for transfusion, embolization); minor (hematuria and hematoma).</p></fn><fn id="tblfn4"><label>d</label><p>Bleeding complications were classified as major (requirement for transfusion, need for embolization, hypotension); minor (hematoma, hematuria).</p></fn><fn id="tblfn5"><label>e</label><p>Bleeding complications were classified primary (flank pain, hematuria, hematoma, need for transfusion, and nephrectomy) and secondary (size of the perinephric hematoma at 6 and 24 hours).</p></fn></table-wrap-foot></table-wrap><p>Collectively, the conflicting and inconsistent outcomes of the available RCTs that used desmopressin as a prophylactic hemostatic measure in patients undergoing PKB can be attributed to several factors. One foundational factor is the lack of standardized definitions of postkidney biopsy complications (Table <xref rid="t1" ref-type="table">1</xref>). Moreover, there is a wide variation in the level of eGFR and mean age among participants in these studies, which makes the interpretation of the results very challenging. This is because both older age and lower eGFR carry a higher risk of PKB complications.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Furthermore, the lack of standardized postprocedure protocol (such as the duration of monitoring and the timing and frequency of US utilization) could contribute to these conflicting outcomes. While in most studies the patients were observed for 24 hours, our group demonstrated that most patients can be discharged within 4&#8211;6 hours after the procedure, specially, if the immediate postbiopsy US is negative for bleeding or hematoma.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Serial kidney US after biopsy arguably will detect more hematomas that often result in a longer hospital stay and more interventions.</p><p>The variation of desmopressin dosing and the route of administration in these RCTs is likely to affect its hemostatic effect, which, in turn, could explain different outcomes of RCTs.</p><p>It is well established that desmopressin administration can elicit a rapid transient increase of plasma levels of both vWF and factor 8 by two- to six-fold that lasts 1&#8211;2 hours.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref></sup> The hemostatic effect of desmopressin is largely ascribed to the increased levels of these factors and subsequent enhanced platelet aggregation. To assure its hemostatic efficacy in different age groups and at different eGFR levels, it is crucial to demonstrate that desmopressin elicits its effects by measuring the levels of both factor 8 and vWF after its administration.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> In doing so, the optimal dose of desmopressin can be determined irrespective of administration route.</p><p>Another important factor that can affect the bleeding complication after PKB is the size of the automated biopsy gun. Accumulative evidence suggests that a larger device size may increase the risk of bleeding after kidney biopsy.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p><p>This study poses more questions than answers and adds more confusion to the role of desmopressin in preventing bleeding complications after PKB. To settle this controversy, high-quality evidence is required before making an informed decision on the use of desmopressin in these procedures.</p><p>In essence, we need a large multicenter RCT that standardizes desmopressin dose and route of administration, as well as the size of the automated biopsy device. The sample size for this RCT needs to be large enough to detect any statistical difference between the intervention and placebo groups. Moreover, post-PKB procedure course needs to be defined for clinical monitoring, obtaining laboratory data, duration of observation, and time intervals of performing kidney US after biopsy.</p><p>Taken together, the evidence for the off-label use of desmopressin before PKB remains nonconclusive. Further large RCTs that address the weaknesses of previous studies are needed to determine the hemostatic efficacy of desmopressin in preventing hemorrhagic complications after kidney biopsy.</p></body><back><ack><title>Acknowledgments</title><p>The content of this article reflects the personal experience and views of the author and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or <italic toggle="yes">Kidney360</italic>. Responsibility for the information and views expressed herein lies entirely with the author.</p></ack><fn-group><fn fn-type="other"><p>See related article, &#8220;Effect of Desmopressin on Post Kidney Biopsy Bleeding Complications in Patients with Reduced Kidney Function: A Randomized Controlled Trial,&#8221; on pages 1350&#8211;1356.</p></fn></fn-group><sec sec-type="COI-statement"><title>Disclosures</title><p>Disclosure forms, as provided by each author, are available with the online version of the article at <ext-link xlink:href="http://links.lww.com/KN9/B198" ext-link-type="uri">http://links.lww.com/KN9/B198</ext-link>.</p></sec><sec sec-type="author-contributions"><title>Author Contributions</title><p><bold>Conceptualization:</bold> Ammar Almehmi.</p><p><bold>Data curation:</bold> Ammar Almehmi.</p><p><bold>Writing &#8211; original draft:</bold> Ammar Almehmi.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Ammar Almehmi.</p></sec><sec sec-type="funding"><title>Funding</title><p>None.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakdash</surname><given-names>K</given-names></name><name name-style="western"><surname>Schramm</surname><given-names>KM</given-names></name><name name-style="western"><surname>Annam</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>K</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>JD</given-names></name></person-group>. <article-title>Complications of percutaneous renal biopsy</article-title>. <source>Semin Intervent Radiol.</source><year>2019</year>;<volume>36</volume>(<issue>2</issue>):<fpage>97</fpage>&#8211;<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0039-1688422</pub-id><pub-id pub-id-type="pmid">31123379</pub-id><pub-id pub-id-type="pmcid">PMC6531025</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poggio</surname><given-names>ED</given-names></name><name name-style="western"><surname>McClelland</surname><given-names>RL</given-names></name><name name-style="western"><surname>Blank</surname><given-names>KN</given-names></name>, <etal/></person-group>.; <collab>Kidney Precision Medicine Project</collab>. <article-title>Systematic review and meta-analysis of native kidney biopsy complications</article-title>. <source>Clin J Am Soc Nephrol.</source><year>2020</year>;<volume>15</volume>(<issue>11</issue>):<fpage>1595</fpage>&#8211;<lpage>1602</lpage>. doi:<pub-id pub-id-type="doi">10.2215/CJN.04710420</pub-id><pub-id pub-id-type="pmid">33060160</pub-id><pub-id pub-id-type="pmcid">PMC7646247</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korbet</surname><given-names>SM</given-names></name><name name-style="western"><surname>Volpini</surname><given-names>KC</given-names></name><name name-style="western"><surname>Whittier</surname><given-names>WL</given-names></name></person-group>. <article-title>Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies</article-title>. <source>Am J Nephrol.</source><year>2014</year>;<volume>39</volume>(<issue>2</issue>):<fpage>153</fpage>&#8211;<lpage>162</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000358334</pub-id><pub-id pub-id-type="pmid">24526094</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weigert</surname><given-names>AL</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>AI</given-names></name></person-group>. <article-title>Uremic bleeding: pathogenesis and therapy</article-title>. <source>Am J Med Sci.</source><year>1998</year>;<volume>316</volume>(<issue>2</issue>):<fpage>94</fpage>&#8211;<lpage>104</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00000441-199808000-00005</pub-id><pub-id pub-id-type="pmid">9704663</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>N</given-names></name><name name-style="western"><surname>Meyyappan</surname><given-names>J</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>DK</given-names></name>, <etal/></person-group>. <article-title>Randomized double-blind placebo-controlled trial of desmopressin for post&#8211;kidney biopsy bleeding</article-title>. <source>Kidney Int Rep.</source><year>2025</year>;<volume>10</volume>(<issue>7</issue>):<fpage>2436</fpage>&#8211;<lpage>2445</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ekir.2025.04.019</pub-id><pub-id pub-id-type="pmid">40677359</pub-id><pub-id pub-id-type="pmcid">PMC12266218</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manno</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonifati</surname><given-names>C</given-names></name><name name-style="western"><surname>Torres</surname><given-names>DD</given-names></name><name name-style="western"><surname>Campobasso</surname><given-names>N</given-names></name><name name-style="western"><surname>Schena</surname><given-names>FP</given-names></name></person-group>. <article-title>Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial</article-title>. <source>Am J Kidney Dis.</source><year>2011</year>;<volume>57</volume>(<issue>6</issue>):<fpage>850</fpage>&#8211;<lpage>855</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2010.12.019</pub-id><pub-id pub-id-type="pmid">21354681</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>B</given-names></name><name name-style="western"><surname>Hadimeri</surname><given-names>H</given-names></name><name name-style="western"><surname>Molne</surname><given-names>J</given-names></name><name name-style="western"><surname>Nasic</surname><given-names>S</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>G</given-names></name><name name-style="western"><surname>Stegmayr</surname><given-names>B</given-names></name></person-group>. <article-title>Desmopressin (Octostim(R)) before a native kidney biopsy can reduce the risk for biopsy complications in patients with impaired renal function: a pilot study</article-title>. <source>Nephrology (Carlton).</source><year>2018</year>;<volume>23</volume>(<issue>4</issue>):<fpage>366</fpage>&#8211;<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1111/nep.13004</pub-id><pub-id pub-id-type="pmid">28107603</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakrabarti</surname><given-names>U</given-names></name><name name-style="western"><surname>Jhorawat</surname><given-names>R</given-names></name><name name-style="western"><surname>Bajpai</surname><given-names>NK</given-names></name>, <etal/></person-group>. <article-title>Effect of desmopressin on post kidney biopsy bleeding complications in patients with reduced kidney function: a randomized controlled trial</article-title>. <source>Kidney360.</source><year>2025</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1350</fpage>&#8211;<lpage>1356</lpage>. doi:<pub-id pub-id-type="doi">10.34067/KID.0000000760</pub-id><pub-id pub-id-type="pmid">40067357</pub-id><pub-id pub-id-type="pmcid">PMC12407119</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethi</surname><given-names>J</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>S</given-names></name><name name-style="western"><surname>Lal</surname><given-names>A</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>HS</given-names></name><name name-style="western"><surname>Rathi</surname><given-names>M</given-names></name></person-group>. <article-title>Role of desmopressin acetate before percutaneous ultrasound-guided kidney biopsy in patients with kidney dysfunction</article-title>. <source>Indian J Nephrol.</source><year>2024</year>;<volume>34</volume>(<issue>3</issue>):<fpage>228</fpage>&#8211;<lpage>232</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijn.ijn_34_23</pub-id><pub-id pub-id-type="pmid">39114394</pub-id><pub-id pub-id-type="pmcid">PMC11302129</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Balas</surname><given-names>A</given-names></name><name name-style="western"><surname>Almehmi</surname><given-names>A</given-names></name><name name-style="western"><surname>Allon</surname><given-names>M</given-names></name></person-group>. <article-title>Value of immediate post-kidney biopsy ultrasound in excluding late hemorrhagic complications</article-title>. <source>Kidney360.</source><year>2020</year>;<volume>1</volume>(<issue>8</issue>):<fpage>797</fpage>&#8211;<lpage>800</lpage>. doi:<pub-id pub-id-type="doi">10.34067/KID.0002212020</pub-id><pub-id pub-id-type="pmid">35372962</pub-id><pub-id pub-id-type="pmcid">PMC8815738</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>